Free Trial

Insmed (INSM) Competitors

Insmed logo
$124.75 +3.59 (+2.96%)
As of 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

INSM vs. REGN, ARGX, NTRA, RVMD, and BIIB

Should you buy Insmed stock or one of its competitors? Insmed's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), and Biogen (BIIB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Insmed compare to Regeneron Pharmaceuticals?

Insmed (NASDAQ:INSM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Insmed's net margin of -39.85%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-39.85% -96.38% -32.55%
Regeneron Pharmaceuticals 28.51%16.01%12.22%

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M43.83-$1.28B-$2.82N/A
Regeneron Pharmaceuticals$14.34B6.89$4.50B$45.2921.10

In the previous week, Regeneron Pharmaceuticals had 11 more articles in the media than Insmed. MarketBeat recorded 19 mentions for Regeneron Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Regeneron Pharmaceuticals' score of 0.62 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Regeneron Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Insmed presently has a consensus price target of $196.52, indicating a potential upside of 62.20%. Regeneron Pharmaceuticals has a consensus price target of $898.97, indicating a potential downside of 5.91%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts clearly believe Insmed is more favorable than Regeneron Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92
Regeneron Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.74

Summary

Regeneron Pharmaceuticals beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to argenex?

argenex (NASDAQ:ARGX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenex$4.25B14.21$1.29B$28.6633.50
Insmed$606.42M43.83-$1.28B-$2.82N/A

argenex has a net margin of 31.66% compared to Insmed's net margin of -39.85%. argenex's return on equity of 47.70% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
argenex31.66% 47.70% 40.12%
Insmed -39.85%-96.38%-32.55%

60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

argenex presently has a consensus price target of $1,155.24, indicating a potential upside of 20.33%. Insmed has a consensus price target of $196.52, indicating a potential upside of 62.20%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

In the previous week, argenex had 9 more articles in the media than Insmed. MarketBeat recorded 17 mentions for argenex and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat argenex's score of 0.52 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
6 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

argenex has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Summary

argenex beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Natera?

Insmed (NASDAQ:INSM) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M43.83-$1.28B-$2.82N/A
Natera$2.31B20.06-$208.16M-$1.14N/A

Natera has a net margin of -5.66% compared to Insmed's net margin of -39.85%. Natera's return on equity of -8.61% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-39.85% -96.38% -32.55%
Natera -5.66%-8.61%-5.93%

99.9% of Natera shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Natera has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

In the previous week, Natera had 8 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Natera and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Natera's score of 0.43 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Insmed presently has a consensus target price of $196.52, indicating a potential upside of 62.20%. Natera has a consensus target price of $394.31, indicating a potential upside of 23.57%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than Natera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83

Summary

Natera beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Insmed (NASDAQ:INSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Revolution Medicines has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M43.83-$1.28B-$2.82N/A
Revolution Medicines$197.56M188.63-$1.13B-$9.11N/A

Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -39.85%. Revolution Medicines' return on equity of -84.51% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-39.85% -96.38% -32.55%
Revolution Medicines N/A -84.51%-51.97%

Insmed currently has a consensus price target of $196.52, suggesting a potential upside of 62.20%. Revolution Medicines has a consensus price target of $262.75, suggesting a potential upside of 52.50%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92

In the previous week, Revolution Medicines had 12 more articles in the media than Insmed. MarketBeat recorded 20 mentions for Revolution Medicines and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Revolution Medicines' score of 0.94 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revolution Medicines
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Revolution Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to Biogen?

Biogen (NASDAQ:BIIB) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Biogen had 16 more articles in the media than Insmed. MarketBeat recorded 24 mentions for Biogen and 8 mentions for Insmed. Biogen's average media sentiment score of 1.33 beat Insmed's score of 1.17 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
17 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Biogen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.79$1.29B$2.34108.29
Insmed$606.42M43.83-$1.28B-$2.82N/A

87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biogen currently has a consensus target price of $254.41, suggesting a potential upside of 0.40%. Insmed has a consensus target price of $196.52, suggesting a potential upside of 62.20%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Biogen has a net margin of 3.37% compared to Insmed's net margin of -39.85%. Biogen's return on equity of 9.38% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Insmed -39.85%-96.38%-32.55%

Summary

Biogen beats Insmed on 10 of the 16 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$27.32B$4.12B$7.91B$11.89B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-44.1624.5634.5230.32
Price / Sales18.0215.348.155.41
Price / CashN/A21.8921.0222.32
Price / Book36.074.454.753.90
Net Income-$1.28B-$24.19M$3.52B$391.39M
7 Day Performance7.50%-5.28%-3.82%-3.22%
1 Month Performance29.65%-2.88%-2.07%-4.61%
1 Year Performance-35.41%-2.71%0.68%-6.60%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
3.3875 of 5 stars
$124.75
+3.0%
$196.52
+57.5%
-37.3%$27.36B$1.52BN/A1,664
REGN
Regeneron Pharmaceuticals
3.7532 of 5 stars
$919.96
+1.7%
$898.97
-2.3%
+37.8%$95.82B$14.34B19.4915,410
ARGX
argenex
4.501 of 5 stars
$962.27
+3.8%
$1,158.76
+20.4%
+5.7%$58.57B$4.25B33.581,863
NTRA
Natera
3.4499 of 5 stars
$320.39
+3.1%
$394.31
+23.1%
+56.2%$56.36B$2.31BN/A6,140
RVMD
Revolution Medicines
3.5015 of 5 stars
$200.15
+4.1%
$263.15
+31.5%
+154.3%$42.80B$11.58MN/A883

Related Companies and Tools


This page (NASDAQ:INSM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners